Abiraterone acetate
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | <StructureSection load='' size='340' side='right' caption=' | + | <StructureSection load='' size='340' side='right' caption='Abiraterone acetate' scene='97/978895/Cv/1'> |
Abiraterone acetate, sold under the brand name Zytiga among others, is a medication used to treat prostate cancer.<ref name="a9">[https://www.drugs.com/monograph/abiraterone.html|"Abiraterone Acetate Monograph for Professionals"]. Drugs.com. Archived from the original on 6 May 2012. Retrieved 15 November 2019.</ref> Specifically it is used together with a [[corticosteroid]] for metastatic castration-resistant prostate cancer (mCRPC) and metastatic high-risk castration-sensitive prostate cancer (mCSPC).<ref name="a2">[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e338e89-3cf2-48eb-b6e2-a06c608c6513|"Zytiga- abiraterone acetate tablet, film coated"]. DailyMed. 13 June 2019. Archived from the original on 13 November 2014. Retrieved 15 November 2019.</ref><ref name="a3">[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b8967e10-f768-47ce-ac9e-2324c8390132|"Yonsa- abiraterone acetate tablet"]. DailyMed. 5 June 2018. Archived from the original on 13 August 2020. Retrieved 15 November 2019.</ref> See also [https://en.wikipedia.org/wiki/Abiraterone_acetate| Abiraterone acetate]. | Abiraterone acetate, sold under the brand name Zytiga among others, is a medication used to treat prostate cancer.<ref name="a9">[https://www.drugs.com/monograph/abiraterone.html|"Abiraterone Acetate Monograph for Professionals"]. Drugs.com. Archived from the original on 6 May 2012. Retrieved 15 November 2019.</ref> Specifically it is used together with a [[corticosteroid]] for metastatic castration-resistant prostate cancer (mCRPC) and metastatic high-risk castration-sensitive prostate cancer (mCSPC).<ref name="a2">[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e338e89-3cf2-48eb-b6e2-a06c608c6513|"Zytiga- abiraterone acetate tablet, film coated"]. DailyMed. 13 June 2019. Archived from the original on 13 November 2014. Retrieved 15 November 2019.</ref><ref name="a3">[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b8967e10-f768-47ce-ac9e-2324c8390132|"Yonsa- abiraterone acetate tablet"]. DailyMed. 5 June 2018. Archived from the original on 13 August 2020. Retrieved 15 November 2019.</ref> See also [https://en.wikipedia.org/wiki/Abiraterone_acetate| Abiraterone acetate]. | ||
Current revision
| |||||||||||
References
- ↑ "Abiraterone Acetate Monograph for Professionals". Drugs.com. Archived from the original on 6 May 2012. Retrieved 15 November 2019.
- ↑ "Zytiga- abiraterone acetate tablet, film coated". DailyMed. 13 June 2019. Archived from the original on 13 November 2014. Retrieved 15 November 2019.
- ↑ "Yonsa- abiraterone acetate tablet". DailyMed. 5 June 2018. Archived from the original on 13 August 2020. Retrieved 15 November 2019.
- ↑ 4.0 4.1 Neidle S (30 September 2013). Cancer Drug Design and Discovery. Academic Press. pp. 341–342. ISBN 978-0-12-397228-6.
- ↑ Fernández-Cancio M, Camats N, Flück CE, Zalewski A, Dick B, Frey BM, Monné R, Torán N, Audí L, Pandey AV. Mechanism of the Dual Activities of Human CYP17A1 and Binding to Anti-Prostate Cancer Drug Abiraterone Revealed by a Novel V366M Mutation Causing 17,20 Lyase Deficiency. Pharmaceuticals (Basel). 2018 Apr 29;11(2):37. PMID:29710837 doi:10.3390/ph11020037
- ↑ Attard G, Belldegrun AS, de Bono JS. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int. 2005 Dec;96(9):1241-6. PMID:16287438 doi:10.1111/j.1464-410X.2005.05821.x
- ↑ Small EJ. Can targeting the androgen receptor in localized prostate cancer provide insights into why men with metastatic castration-resistant prostate cancer die? J Clin Oncol. 2014 Nov 20;32(33):3689-91. PMID:25311216 doi:10.1200/JCO.2014.57.8534
